TriSalus Life Sciences (TLSI) AI Stock Analysis

• Market Cap: $277.30M
• Dividend Yield: N/A
• Average Volume (3M): 111.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: 49.52%
• EPS Growth: 19.34%
• Country: US
• Employees: 110
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.96
• Shares Outstanding: 49,964,310
• 10 Day Avg. Volume: 121,366
• 30 Day Avg. Volume: 111,130
• PEG Ratio: 0.09
• Price to Book (P/B): -5.13
• Price to Sales (P/S): 4.51
• P/FCF Ratio: -3.22
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: 5.26
• Enterprise Value/Gross Profit: 6.26
• Enterprise Value/Ebitda: -6.28
• 1Y Price Target: $11.60
• Price Target Upside: 109.01% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -1.55
• Revenue Forecast (FY): $44.74M

• Rating: 51 Neutral
• Price Target: $5.00 ▼(-9.91% Downside)

TriSalus Life Sciences' overall stock score is primarily impacted by its financial challenges, including persistent losses and a weak balance sheet. While technical indicators show positive momentum, and the earnings call suggests strategic growth opportunities, the negative valuation metrics and financial instability weigh heavily on the score.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product adoption, positioning the company for continued expansion in the oncology sector.

Product Expansion

Expanding the product portfolio enhances market opportunities and strengthens the company's competitive position in delivering innovative cancer therapies.

Reimbursement Expansion

Increased reimbursement potential boosts revenue streams and supports broader adoption of the company's technology in the healthcare market.

Negative Factors

Financial Instability

A weak balance sheet with negative equity and high debt levels poses risks to financial stability and limits flexibility for future investments.

Cash Flow Challenges

Persistent cash flow issues can hinder operational capabilities and strategic initiatives, impacting long-term growth and sustainability.

Profitability Issues

Ongoing profitability challenges highlight the need for cost management and efficiency improvements to achieve sustainable financial performance.

TriSalus Life Sciences Business Overview & Revenue Model

Company Description

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

How the Company Makes Money

TriSalus Life Sciences generates revenue through various channels, including the commercialization of its drug delivery technologies and therapeutic products. The company primarily earns income from partnerships and collaborations with pharmaceutical companies, which may involve licensing agreements, research funding, and milestone payments tied to the development of new therapies. Additionally, TriSalus may generate revenue through clinical trial services and consulting, providing expertise in treatment protocols for solid tumors. The company's focus on innovative delivery mechanisms for existing and new cancer therapies positions it to capitalize on the growing oncology market, making strategic partnerships critical to its financial success.

TriSalus Life Sciences Financial Statement Overview

Summary

TriSalus Life Sciences faces significant financial challenges, with strong revenue growth overshadowed by persistent losses and a weak balance sheet. The company's high gross profit margin is a positive, but negative equity and cash flow issues pose substantial risks. Strategic improvements in profitability and financial stability are essential for future success.

Income Statement

TriSalus Life Sciences shows a strong gross profit margin of 84.67% TTM, indicating efficient cost management. However, the company struggles with profitability, as evidenced by a negative net profit margin of -86.61% TTM and negative EBIT and EBITDA margins. Revenue growth is positive at 11.72% TTM, but the consistent losses highlight challenges in achieving profitability.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity, leading to a high debt-to-equity ratio of -1.73 TTM. This indicates financial instability and potential risk. Return on equity is positive at 124.53% TTM, but this is due to negative equity, which distorts the metric. The equity ratio is also negative, reflecting a weak capital structure.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a decline in free cash flow growth by -24.24% TTM. The operating cash flow to net income ratio is -3.04 TTM, indicating cash flow challenges. However, the free cash flow to net income ratio is slightly positive at 1.03 TTM, suggesting some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	40.21M	29.43M	18.51M	12.40M	8.40M	0.00
Gross Profit	33.79M	25.33M	15.91M	10.14M	7.21M	0.00
EBITDA	-33.72M	-36.16M	-58.65M	-46.76M	-23.57M	-711.39K
Net Income	-39.58M	-33.23M	-59.36M	-47.19M	-28.84M	-31.83M
Balance Sheet
Total Assets	36.46M	23.97M	24.60M	22.00M	37.84M	8.13M
Cash, Cash Equivalents and Short-Term Investments	22.69M	8.53M	11.78M	9.41M	30.30M	4.49M
Total Debt	34.12M	23.63M	1.59M	1.96M	0.00	42.18M
Total Liabilities	63.19M	49.87M	51.66M	34.32M	6.93M	58.28M
Stockholders Equity	-26.73M	-25.89M	-27.07M	-12.32M	30.90M	-50.16M
Cash Flow
Free Cash Flow	-22.16M	-41.19M	-51.17M	-33.10M	-23.95M	-677.60K
Operating Cash Flow	-21.23M	-40.84M	-50.58M	-32.31M	-22.70M	-677.60K
Investing Cash Flow	-847.00K	-345.00K	-1.59M	-1.79M	-2.26M	-250.00M
Financing Cash Flow	33.48M	37.94M	54.63M	13.46M	50.77M	252.01M

TriSalus Life Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TLSI, the sentiment is Positive. The current price of 5.55 is above the 20-day moving average (MA) of 4.63, above the 50-day MA of 4.73, and above the 200-day MA of 5.04, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 69.97 is Neutral, neither overbought nor oversold. The STOCH value of 89.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TLSI.

TriSalus Life Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	68 Neutral	$253.20M	20.15	10.53%	―	18.90%	29.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TLSI	51 Neutral	$277.30M	―	―	―	49.52%	19.34%
CVRX	49 Neutral	$258.17M	―	-91.88%	―	18.44%	25.42%
INGN	48 Neutral	$192.21M	―	-13.27%	―	4.68%	55.37%
NNOX	47 Neutral	$278.00M	―	-34.75%	―	15.19%	-3.32%
OM	42 Neutral	$77.79M	―	-92.33%	―	4.65%	68.71%

TriSalus Life Sciences Corporate Events

Trisalus Life Sciences Reports Strong Earnings Amid Challenges

Trisalus Life Sciences, Inc. recently held its earnings call, revealing a mixed sentiment. The company showcased significant revenue growth and strategic expansions, particularly with its TriNav platform, indicating strong market momentum. However, challenges such as declining gross margins, increased R&D expenses, and higher operating losses were also highlighted, pointing to areas that require attention. Despite these hurdles, the company remains optimistic about its strategic investments and market opportunities, which are expected to drive continued growth.

TriSalus Life Sciences Reports Strong Revenue Growth

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that integrates innovative delivery technology with standard-of-care therapies to improve outcomes for patients with solid tumors. The company is known for its proprietary Pressure-Enabled Drug Delivery (PEDD) technology and investigational immunotherapeutic, nelitolimod.

TriSalus Life Sciences Grants CFO Stock Options

On August 25, 2025, TriSalus Life Sciences, Inc. approved an increase in the annual compensation of their Chief Financial Officer, Mr. David Patience, from $450,000 to $550,000. Additionally, on August 28, 2025, the company granted Mr. Patience stock options to purchase 249,899 shares of common stock, contingent upon the company achieving or exceeding $75 million in revenue over a twelve-month period before the end of 2027.

The most recent analyst rating on (TLSI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on TriSalus Life Sciences stock, see the TLSI Stock Forecast page.